Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Gilead Sciences | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Gilead Sciences

Product revenues rise, offset by drop in Tamiflu royalties

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences 4Q10

4Q Revenues: $2.0 billion (-1%)

4Q Earnings: $629 million (-22%)

FY Revenues: $7.9 billion (+13%)

FY Earnings: $2.9 billion (+10%)

Comments: The drop in 4Q revenues was due primarily to reduced Tamiflu revenues from the company’s royalty agreement with Roche; 4Q10 royalty revenues fell to $21.9 million from $194.1 million. Product sales rose 7% in 4Q10 to $1.9 billion, due mainly to the antiviral franchise. For FY10, product revenues were up 14% to $7.4 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters